Therapeutic strategies to reduce IL-1 activity in treating local and systemic inflammation.

Current opinion in pharmacology (2004-07-15)
Charles A Dinarello
RESUMEN

All biological agents currently used for reducing TNFalpha activity in disease are neutralization strategies; however, there are several strategies for reducing interleukin (IL)-1 activities: the IL-1 receptor antagonist (IL-1Ra), anti-IL-1beta monoclonal antibodies, the IL-1 Trap, IL-1 receptor type I antibodies, antibodies to the IL-1 receptor accessory chain and inhibitors of IL-1beta-converting enzyme, now termed caspase-1. In fact, caspase-1 inhibitors are the first orally active agents that target cytokines, as these inhibitors prevent the processing and release of active forms for IL-1beta and IL-18, which is a member of the IL-1 family. The IL-1 Trap is a new concept in using soluble forms of cytokine receptors to bind and neutralize a specific cytokine. The Trap takes advantage of the high affinity of the two signaling chains of the cell surface IL-1 receptor linked by the Fc portion of IgG1. The IL-1Ra is currently approved to treat rheumatoid arthritis; in over 75 000 patients, the IL-1Ra has provided insights into the role of IL-1 in local and systemic inflammation, as well as the safety of long-term reduction of IL-1 activity.

MATERIALES
Referencia del producto
Marca
Descripción del producto

Sigma-Aldrich
Anti-Interleukin-1β antibody produced in goat, IgG fraction of antiserum
Sigma-Aldrich
Anti-IL1B antibody produced in rabbit, affinity isolated antibody
Sigma-Aldrich
Anti-Interleukin-1α antibody produced in goat, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Anti-Interleukin-1α antibody produced in goat, affinity isolated antibody, lyophilized powder
Sigma-Aldrich
Anti-Interleukin-1α antibody produced in goat, IgG fraction of antiserum, lyophilized powder
Sigma-Aldrich
Monoclonal Anti-Interleukin-1α propeptide antibody produced in mouse, clone 409405, purified immunoglobulin, lyophilized powder
Sigma-Aldrich
Anti-Interleukin-1α antibody produced in goat, IgG fraction of antiserum, lyophilized powder

Redes sociales

LinkedIn icon
Twitter icon
Facebook Icon
Instagram Icon

Merck

Investigación. Desarrollo. Producción.

Somos un proveedor líder para la industria de Ciencias de la Vida con soluciones y servicios para investigación, desarrollo y producción biotecnológicos, y para desarrollo y producción de tratamientos farmacéuticos

© 2021 Merck KGaA, Darmstadt, Alemania y/o sus filiales. Todos los derechos reservados.

Queda estrictamente prohibida la reproducción sin permiso de cualquiera de los materiales de la página web.